National guidelines for the management of absolute cardiovascular disease risk

Med J Aust. 2013 Aug 19;199(4):243-4. doi: 10.5694/mja13.10248.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Australia
  • Calcium Channel Blockers / therapeutic use
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / prevention & control*
  • Disease Management
  • Diuretics / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • National Health Programs / organization & administration*
  • Practice Guidelines as Topic*
  • Preventive Health Services / standards*
  • Primary Health Care / standards*

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Calcium Channel Blockers
  • Diuretics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors